A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

Trial Profile

A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Regorafenib
  • Indications Colorectal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
    • 18 Jan 2017 This trial has been completed in Spain (end date: 17 Dec 2016).
    • 16 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top